Welcome to the October/November 2004 edition of TSC Alert – an online research newsletter for individuals interested in Tuberous Sclerosis Complex (TSC) research and clinical care. This online newsletter contains information of interest to the TSC research and health care community. Please forward this newsletter to colleagues who are interested in TSC. To be added/deleted to/from the mailing list for TSC Alert and/or to submit information for the December 2004 TSC Alert contact: Vicky.Whittemore@tsalliance.org

Table of Contents

[Clicking on one of the headings takes you directly to that section of TSC Alert]

IMPORTANT DEADLINES: ........................................................................................................... 1
GRANT ANNOUNCEMENTS: ................................................................................................. 2
TISSUE AVAILABILITY: ........................................................................................................... 3
NEW TSC PUBLICATIONS: ....................................................................................................... 4
CONFERENCES: ........................................................................................................................ 7
NEWS: ........................................................................................................................................ 8
ARCHIVED ISSUES OF TSC ALERT: ...................................................................................... 10

IMPORTANT DEADLINES:

TUBEROUS SCLEROSIS ALLIANCE
Deadline for Letters of Intent: November 12, 2004
(See information below in Grant Announcements)

TUBEROUS SCLEROSIS COMPLEX RESEARCH PROGRAM (TSCRP) IN THE CDRMP
Deadline: February 22, 2005
(See information below in Grant Announcements)
**TSC/LAM Research Conference – Call for Abstracts!**
Deadline for submission of abstracts: January 14, 2005
Deadline for submission of Late-breaking Abstracts: March 15, 2005
Deadline for Registration: February 18, 2005
(See information below in Conferences)

**SOLICITING NOMINATIONS FOR MANUEL R. GOMEZ AWARD**
Deadline for submission of nominations: February 1, 2005
(See information below in News)

**GRANT ANNOUNCEMENTS:**

**TUBEROUS SCLEROSIS ALLIANCE**
Deadline for Letters of Intent: November 12, 2004

The Tuberous Sclerosis Alliance has released a Request for Applications (RFA). Funding will be provided for postdoctoral fellows, junior and senior investigator awards, as well as for conference grants. A Letter of Intent (LOI) is required prior to submission of a grant application and the PI will be invited to submit a complete grant proposal by the January 28, 2005 deadline. These grants are available to all clinical and basic researchers for proposals pertaining to TSC and are not restricted to grants in the U.S.A.

For more information, see the TS Alliance Web site at: [http://www.tsalliance.org](http://www.tsalliance.org)

**TUBEROUS SCLEROSIS COMPLEX RESEARCH PROGRAM (TSCRP) IN THE CDRMP**
Deadline: February 22, 2005

The Fiscal Year 2005 (FY05) Defense Appropriations Act provides $3.2 million to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative research directed toward improved prevention, diagnosis, and treatment of TSC. This program is administered by the US Army Medical Research and Materiel Command through the Office of the Congressionally Directed Medical Research Programs (CDMRP).

FY05 TSCRP Program Announcements for the following mechanisms are expected to be released in early November 2004, with receipt of electronic submissions due February 22, 2005 at 5:00 p.m. Eastern time:

- Natural History Study Awards - New
- Natural History Development Awards
- Concept Awards
- Idea Development Awards

Detailed descriptions of each mechanism will be provided in the FY05 TSCRP Program Announcements, which are expected to be posted on the CDMRP website in early November. Requests for e-mail notification of the Program Announcement release may be sent to prequest@constellagroup.com. For more information about the TSCR or other CDMRP-
sponsored programs, please visit the CDMRP website at: 

SMALL GRANTS PROGRAM FOR CANCER EPIDEMIOLOGY (PAR-04-159) 
National Cancer Institute
Application Receipt Date(s): November 21, 2005; March 20, 2006; 
July 20, 2006; November 20, 2006; March 20, 2007; July 20, 2007; 
November 20, 2007; March 20, 2008; July 21, 2008; November 21, 2008 

NIH ANNOUNCES REVISED POLICY: APPLICATIONS THAT INCLUDE CONSORTIUM/ 
CONTRACTUAL FACILITIES AND ADMINISTRATIVE COSTS (NOT-OD-05-004) 
National Institutes of Health

SKIN DISEASES RESEARCH CORE CENTERS (RFA-AR-05-002) 
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Application Receipt Date(s): May 24, 2005

TYPICAL/DISORDERED LANGUAGE: PHENOTYPE ASSESSMENT TOOLS (RFA-DC-05-001) 
National Institute on Deafness and Other Communication Disorders
National Institute of Child Health and Human Development
Application Receipt Date(s): February 24, 2005

REVIEW OF RANKING DATA (NOT-OD-05-008) 
National Institutes of Health

TISSUE AVAILABILITY:

If you are interested in obtaining tissue for your research, please contact the Brain and Tissue Bank at 1-800-847-1539 or visit their Web site at:  http://som1.umaryland.edu/braintissuebank

If you have specific needs for TSC tissue for your research, please contact Vicky Whittemore at vwhittemore1@comcast.net or Vicky.whittemore@tsalliance.org
NEW TSC PUBLICATIONS:


Signaling by insulin and target of rapamycin are both required for cell growth, but their interrelationships remain poorly defined. It was reported that Akt, an essential component of the insulin pathway, stimulates growth by phosphorylating and inhibiting tuberous sclerosis complex 2 (TSC2). Here Dong and Pan evaluated this model genetically in Drosophila by engineering Tsc2 mutants in which the Akt phosphorylation sites were changed to nonphosphorylatable or phospho-mimicking residues. Strikingly, such mutants completely rescued the lethality and cell growth defects of Tsc2-null mutants. Taken together, their data suggest that Tsc2 is not a critical substrate of Akt in normal Drosophila development.

Note: Dr. Duojia D.J. Pan has recently accepted a position as Associate Professor in the Department of Molecular Biology and Genetics at Johns Hopkins University.


This study set out to describe the clinical presentations, radiologic features, and postoperative outcomes of a clinic-based population of patients with subependymal giant cell tumors (SGCT) and tuberous sclerosis complex (TSC) and to redefine and reclassify SGCT based on radiologic, clinical, and pathologic criteria. Of 134 TSC patients evaluated from December 2001 to November 2003, 11 (8.2%) had undergone resection of a pathologically confirmed SGCT. The authors reviewed the medical records of each case. Follow-up ranged from 2 months to 36 years. Four individuals were asymptomatic at the time of resection while the other seven presented subacutely with fatigue, decreased appetite, headache, increased seizure frequency, visual field deficit, cognitive decline, or behavioral problems. Poor outcomes occurred in all patients aged 11 years or older at the time of resection. Subependymal giant cell tumors in patients with TSC appear to be of mixed glioneuronal lineage, and, therefore, the current practice of classifying these tumors as astrocytomas merits revision. The clinical diagnosis of SGCT should be made for subependymal lesions in TSC that are associated with symptoms, papilledema, or radiologic evidence of hydrocephalus or interval growth. A diagnosis of probable SGCT should be made when a lesion has the potential to cause obstruction based on size or location. Annual screening by MRI with or without contrast is indicated until at least 21 years of age even if subependymal nodules are absent on initial imaging. A diagnosis of SGCT or probable SGCT warrants more frequent monitoring or surgical intervention.

**TSC PUBLICATIONS:**


Surg 39(10):1586-9


CONFERENCES:

For a complete listing of conferences, visit the TS Alliance website at:
http://216.33.101.121/Research/upcoming%20conferences.asp

December 3-7, 2004
American Epilepsy Society Meeting
Convention Center, New Orleans, LA
➢ Stop by the TS Alliance exhibit at the meeting!

January 27-28, 2005
National Coalition for Health Professional Education in Genetics (NCHPEG) &
Genetics Resources on the Web (GROW) 8th Annual Meeting: Focus on Family History
Hyatt Regency Bethesda, Bethesda, MD
For more information: http://www.nchpeg.org

February 19-20, 2005
West Coast Regional TSC Conference
Mission Inn, Riverside, CA
Sponsored and organized by the Community Alliance of the Tuberous Sclerosis Alliance
For more information, contact April Cooper at ACoope@ardenrealty.com

April 8-10, 2005
TSC/LAM Research Conference & TSC Adult Conference
The Hyatt Regency, Downtown Cincinnati, OH
Organized by the Tuberous Sclerosis Alliance, LAM Foundation, and Rare Lung Disease
Consortium

The Tuberous Sclerosis Alliance and the LAM Foundation invite you to attend the first joint
TSC/LAM conference in Cincinnati, Ohio in April 2005. Sessions will include:
• The TSC Genes in the Brain – What Do They Do?
• Signaling Pathways and Basic Biology of TSC1/TSC2
• TSC-LAM Translational Research
• What Causes Epilepsy in TSC?
• Behavioral Phenotypes in TSC
• Late-Breaking Science and Roadmap for a Cure for TSC

CALL FOR ABSTRACTS
Platform and poster presentations will be selected from submitted abstracts based on scientific
merit and thematic considerations. The application and instructions are enclosed and may also be
completed electronically or downloaded from the Tuberous Sclerosis Alliance Web site at
http://www.tsalliance.org or The LAM Foundation website at http://lam.uc.edu

Deadline for submission of abstracts: January 14, 2005
Deadline for submission of Late-Breaking TSC Abstracts: March 15, 2005
Deadline for Registration: February 18, 2005
For more information, Call for Abstracts, Agenda and Registration information:
http://www.tsalliance.org
Save the date!  May 4-5, 2006
TSC International Research Conference 2006
Berlin, Germany
More information coming soon!

NEWS:

SOLICITING NOMINATIONS FOR MANUEL R. GOMEZ AWARD  The Tuberous Sclerosis
Alliance is soliciting nominations for the Manuel R. Gomez Award. Individuals who have made
significant contributions toward our understanding of tuberous sclerosis complex (TSC) either
through their research and/or by providing clinical care for individuals with TSC may be
nominated. The award will be presented at the TSC/LAM Research Conference in Cincinnati,
Ohio in April 2005.

Nominations should include a letter of nomination detailing the individual's contribution(s) to TSC
research and/or clinical care and a complete and up-to-date copy of their CV. Nominations
should be submitted to:
Manuel R. Gomez Award Committee
Tuberous Sclerosis Alliance
801 Roeder Road, Suite 750
Silver Spring, MD  20910

Deadline for submission of nominations is February 1, 2005.

TEXTPRESSO’S RICHER BLEND OF SCIENTIFIC DATA  Frustrated that the volume and
increasing complexity of the scientific literature might make it impossible for researchers to keep
pace, HHMI researchers have developed Textpresso, a new text-mining system that sifts through
the literature and identifies relevant information nearly as well as human document curators.
This research Paul W. Sternberg, Ph.D., at the California Institute of Technology was published in
the October 04, 2004, issue of Public Library of Science (PLoS) Biology. For the full story, go to
http://www.hhmi.org//news/sternberg2.html

HUMAN BLOOD GENOMICS: DISTINCT PROFILES FOR GENDER, AGE AND
NEUROFIBROMATOSIS TYPE  Dr. Yang Tang and coworkers demonstrated that the NF1 gene
mutation or the presence of the Y chromosome can cause specific gene expression patterns in
peripheral blood cells even though no obvious phenotypes are observed in the blood. This finding
suggests that peripheral blood can be used to study functional genomics and phenotypes of
 genetic diseases and blood genomic expression profiling holds promise for providing molecular
markers for the effects of genetic diseases on end-organs. For more information:
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T07-4BC2MB8-
1&_coverDate=01%2F01%2F2004&_alid=211890890&_rdoc=1&_fmt=&_orig=search&_qd=1&
_cdi=4855&_sort=d&view=c&acct=C000050221&_version=1&_urlVersion=0&userid=10&md5=
5b8b5b0e69a30a01ae2818d764974084

HHMI UNVEILS SCIENTIFIC PROGRAM AND RECRUITMENT STRATEGY FOR THE
JANELIA FARM RESEARCH CAMPUS  Howard Hughes Medical Institute (HHMI) announced
today that it is commencing recruitment for scientific group leaders for its Janelia Farm Research Campus, which is currently being constructed in Ashburn, Virginia. The Institute has also identified two broad areas of scientific inquiry that are well suited to Janelia Farm: The identification of general principles that govern how information is processed by neuronal circuits; and the development of imaging technologies and computational methods for image analysis. As HHMI’s first freestanding campus, Janelia Farm will provide a setting in which small research groups can explore fundamental biomedical questions in a highly collaborative, interdisciplinary culture. The $500 million campus will open in late 2006. To read the full story, go to http://www.hhmi.org/news/100404.html

**WITHOUT DOPAMINE, NEURONS CONTINUE TO FIRE NORMALLY** Researchers are learning whether normal neuron behavior depends on the ability to produce an essential neurotransmitter. Recent studies in living mice by Richard D. Palmiter, Ph.D., at the University of Washington School of Medicine, indicate that dopamine-producing neurons are capable of triggering nerve impulses even when they are deprived of dopamine. This research was published in the September 07, 2004, issue of Proceedings of the National Academy of Sciences. For the full story, go to http://www.hhmi.org/news/palmiter2.html

**NIH Releases Guidelines on DNA Use** The NIH has released a notice, “Compliance with The NIH Guidelines for Research Involving Recombinant DNA Molecules” reminding researchers of rules and highlights some of the required compliance activities.

**RESEARCHERS BOWLED OVER BY GLUTAMATE TRANSPORTER’S ELEGANT ARCHITECTURE** X-ray crystallography studies BY Eric Gouaux, Ph.D. at Columbia University College of Physicians and Surgeons, reveal the inner beauty of a transporter protein that vacuums up the neurotransmitter glutamate. To solve the structure, HHMI scientists turned to an extreme organism, Pyrococcus horikoshii, a bacterium that has adapted to life in boiling undersea vents. The studies of the glutamate transporter’s structure could aid the development of new drugs to treat a wide range of disorders. For the full story, go to http://www.hhmi.org/news/gouaux.html

**NEW ANIMAL LAW WEB SITE** The National Association for Biomedical Research has announced the launch of a new animal law Web site for anyone looking for information on animals and the law.

**Public Comment Period on Public Access to Research** NIH has released a notice on “Enhanced Public Access to NIH Research Information,” This notice is to announce and to seek public comments regarding NIH’s plans to facilitate enhanced public access to NIH health related research information.

Sciences. The workshop will explore scientific and ethical aspects of issues related to human embryonic stem cell research, including nuclear transplantation (the use of somatic cell nuclear transfer to create stem cells) among other topics, and provide a forum for the expression of different viewpoints about the appropriate scope and content of guidelines for this emerging research field.

**NIMH GRANT TO EXPLORE GENETICS OF AUTISM.** The National Institute of Mental Health (NIMH), part of the National Institutes of Health, announced this week a 3-year, $3 million grant to Johns Hopkins University to study the genetic factors underlying autism.

In an average year, 2 to 6 new cases of Autism, a neuropsychiatric disorder, arise per 1,000 children. While at least 80 percent of the disorder is due to hereditary factors, experts believe it develops from an interaction between environmental factors and multiple unknown genes. The Johns Hopkins research team, led by Aravinda Chakravarti, Ph.D., proposes to use new genetic analysis technologies to dissect the complex neuropsychiatric traits of autism.

"Although the role of hereditary factors in autism is not in doubt, their nature remains elusive and no single causal gene has yet been identified," said NIMH Director Thomas R. Insel, M.D. "This initiative is part of a group of projects put forward by NIMH to begin unraveling the underlying genetics of autism."

The study will apply novel statistical methods and molecular technologies to identify specific genetic markers, or polymorphisms -- naturally-occurring genetic variations -- that may be related to autism. To accomplish this, the researchers will use DNA and clinical data from the NIMH Human Genetics Initiative (http://www.nimhgenetics.org) and the Autism Genetic Research Exchange (http://www.agre.org), two large repositories of research resources available to the scientific community. The investigators aim to identify specific gene variants that contribute to vulnerability to autism.

**ARCHIVED ISSUES OF TSC ALERT:**

http://www.tsalliance.org/Research/TSC%20Alert.asp